Here's hoping this drug will benefit some of us in the ME/CFS/SEID/PENIS community as well. Looks promising!
FAST TRACK APPROVAL FOR SFN DRUG ARA290
APRIL 16, 2015 JULES PRAST LEAVE A COMMENT
The trials with ARA 290, an experimental drug developed to treat sarcoidosis induced small fiber neuropathy, have continued into international phase 2c. What hurdles will have to be taken before it is available for patients? An interview with Chief Executive Officer of Araim Pharmaceuticals Inc., Dr. Anthony Cerami, who is developing the new first-in-class drug
Biochemist Dr Antony Cerami strongly believes in the potential of ARA 290. However, it will be quite some time before it is approved for use in sarcoidosis induced Small Fiber Neuropathy (SFN). ARA 290 is a unique compound that turns off inflammation and demonstrates the potential to reduce neuropathic pain and repair damaged small nerves. This may lead to a reduction of pain and an improvement of autonomic symptoms such as dry eyes, palpitations and dizziness. Moreover, the results of clinical trials give hope that ARA 290 can diminish the chronic fatigue many patients suffer from.
Click here for the full interview (pdf, 2.4MB)
Source: SarcoScoop, Quarterly Magazine of the Sarcoidosis Society of the Netherlands, December 2014 issue